Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
Valentina Ambrosini, Jolanta Kunikowska, Eric Baudin, et al.
European Journal of Cancer (2021) Vol. 146, pp. 56-73
Open Access | Times Cited: 190

Showing 1-25 of 190 citing articles:

Radiation therapy‐associated toxicity: Etiology, management, and prevention
Kyle Wang, Joel E. Tepper
CA A Cancer Journal for Clinicians (2021) Vol. 71, Iss. 5, pp. 437-454
Open Access | Times Cited: 281
Advances in PET imaging of cancer
Johannes Schwenck, Dominik Sonanini, Jonathan Cotton, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 7, pp. 474-490
Closed Access | Times Cited: 113
European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours
Beata Kos‐Kudła, Justo P. Castaño, Timm Denecke, et al.
Journal of Neuroendocrinology (2023) Vol. 35, Iss. 12
Open Access | Times Cited: 94
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma
Halfdan Sørbye, Enrique Grande, Marianne Pavel, et al.
Journal of Neuroendocrinology (2023) Vol. 35, Iss. 3
Open Access | Times Cited: 92
Radiotheranostics in oncology: Making precision medicine possible
Eric O. Aboagye, Tara Barwick, Uwe Haberkorn
CA A Cancer Journal for Clinicians (2023) Vol. 73, Iss. 3, pp. 255-274
Open Access | Times Cited: 72
Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants
David Taïeb, George B. Wanna, Maleeha Ahmad, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 5, pp. 345-361
Open Access | Times Cited: 54
Theranostics and artificial intelligence: new frontiers in personalized medicine
Gokce Belge Bilgin, Cem Bilgin, Brian J. Burkett, et al.
Theranostics (2024) Vol. 14, Iss. 6, pp. 2367-2378
Open Access | Times Cited: 29
Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
Mercedes Mitjavila, Paula Jiménez‐Fonseca, Pilar Belló, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 8, pp. 2486-2500
Open Access | Times Cited: 32
161Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer
Akram Al‐Ibraheem, Andrew M. Scott
Nuclear Medicine and Molecular Imaging (2023) Vol. 57, Iss. 4, pp. 168-171
Closed Access | Times Cited: 31
Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE
Luca Urso, Alberto Nieri, Licia Uccelli, et al.
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1110-1110
Open Access | Times Cited: 27
Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
Elettra Merola, Chiara Maria Grana
Cancers (2023) Vol. 15, Iss. 11, pp. 2975-2975
Open Access | Times Cited: 23
Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023
Gianpaolo di Santo, Giulia Santo, Anna Sviridenko, et al.
Theranostics (2024) Vol. 14, Iss. 3, pp. 940-953
Open Access | Times Cited: 14
Gastric neuroendocrine neoplasms
Giuseppe Lamberti, Francesco Panzuto, Marianne Pavel, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 13
Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET)
Riccardo Laudicella, Domenico Albano, Matteo Bauckneht, et al.
Clinical and Translational Imaging (2025)
Open Access | Times Cited: 1
Nuclear medicine and perspective thoughts in the diagnosis and treatment of pheochromocytoma and paraganglioma
Emirhan Harbi, Michael Aschner
Journal of Neuroendocrinology (2025)
Closed Access | Times Cited: 1
Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
Sonya Park, Ashwin Singh Parihar, Lisa Bodei, et al.
Journal of Nuclear Medicine (2021) Vol. 62, Iss. 10, pp. 1323-1329
Open Access | Times Cited: 52
PSMA Theranostics: Current Landscape and Future Outlook
Han‐Bo Zhang, Stella Koumna, Frédéric Pouliot, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 4023-4023
Open Access | Times Cited: 47
Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals
Melpomeni Fani, Rosalba Mansi, Guillaume Nicolas, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1172-1172
Open Access | Times Cited: 36
A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
Morticia N. Becx, Noémie S. Minczeles, Tessa Brabander, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5792-5792
Open Access | Times Cited: 31
Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
Berthold A. Nock, Panagiotis Kanellopoulos, Lieke Joosten, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 674-674
Open Access | Times Cited: 18
Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update
Martina Di Franco, Lucia Zanoni, Emilia Fortunati, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 5, pp. 538-550
Open Access | Times Cited: 8
Neuroendocrine neoplasms of the pancreas: diagnosis and pitfalls
Björn Konukiewitz, Moritz Jesinghaus, Atsuko Kasajima, et al.
Virchows Archiv (2021) Vol. 480, Iss. 2, pp. 247-257
Open Access | Times Cited: 41
Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies
Niloefar Ahmadi Bidakhvidi, Karolien Goffin, Jeroen Dekervel, et al.
Cancers (2021) Vol. 14, Iss. 1, pp. 129-129
Open Access | Times Cited: 36
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
Valentina Ambrosini, Lucia Zanoni, Angelina Filice, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 1055-1055
Open Access | Times Cited: 27
Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?
Thomas A. Hope, Marianne Pavel, Emily K. Bergsland
Journal of Clinical Oncology (2022) Vol. 40, Iss. 24, pp. 2818-2829
Open Access | Times Cited: 26
Page 1 - Next Page

Scroll to top